Biotechnology Industry Organization

Biotechnology Industry Organization is an industry lobby group founded 1993 in Washington, D.C. The current President is James C. Greenwood, while Carl B. Feldbaum was the president until he retired in 2004.

Source: Wikipedia

Campaign Finance

Information

Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:

  • contributions under $200 are not reported, and so are not included in totals.
  • only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
  • contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
  • corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
  • organization totals include known subsidiaries of the organization.

For more information, please see our campaign finance methodology page. Lobbyist bundling data is described on our lobbyist bundling methodology page.

Latest FEC Data

covers through committee's October 17, 2012 filing.
Download all contributions to Biotechnology Industry Organization

  • Summary

    overview of the committee's finances
    Total Raised:
    $207,561
    Total Spent:
    $200,479
    Cash on Hand:
    $66,221
    Debts:
    $0

Standardized Donation Information

covers through June 2012. may lag behind FEC section above, as donors and industries are identified by hand.

  • Top Recipients

    Employee Color Block
    Individuals
    PAC Color Block
    PAC
    Includes contributions from the organization’s employees, their family members, and its political action committee.

  • Republicans vs. Democrats

    in dollars. "Other" includes 3rd parties and organizations without official party affiliation.

  • State vs. Federal

    in dollars

  • Top PAC Recipients

    Employee Color Block
    Individuals
    PAC Color Block
    PAC
    Includes contributions from the organization’s employees, their family members, and its political action committee.
View all campaign finance data for Biotechnology Industry Organization Sources: OpenSecrets.org FollowTheMoney.org

Lobbying

$11,880,000 Spent
Information

Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.

For more information, please see our lobbying methodology page.

covers through Q2, 2012

Lobbying On Behalf of Biotechnology Industry Organization

View all lobbying data for Biotechnology Industry Organization Sources: Lobbyist Registration Tracker OpenSecrets.org

Regulations

33 Mentions; 10 Submissions
Information

All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.

Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.

Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.

Regulations and public comments can be downloaded in bulk here.

updated from Regulations.gov on September 27, 2011

The tables show occurrences of "Biotechnology Industry Organization" in public comments on proposed federal regulations.

  • Documents Submitted by the Organization
    • Submissions
    • Agency
    • Docket
    • Date
    • Toggle 1 FDA Draft Guidance for Industry and FDA Staff on Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets; Availability 2011
    • Toggle 1 ITA Request for Public Comments Concerning Regulatory Cooperation between the United States and the European Union that Would Help Eliminate or Reduce Unnecessary Divergences in Regulation and in Standards Used in Regulation that Impede U.S. Exports 2011
    • Toggle 1 FDA Biologics Price Competition and Innovation Act of 2009; Options for a User Fee Program for Biosimilar and Interchangeable Biological Product Applications for Fiscal Years 2013 through 2017; Request for Comments 2011
    • Toggle 1 ITA Request for Public Comments Concerning Regulatory Cooperation Activities that Would Help Eliminate or Reduce Unnecessary Regulatory Divergences in North America that Disrupt U.S. Exports 2011
    • Toggle 1 FDA Draft Guidance for Industry on Safety Labeling Changes; Implementation of the Federal Food, Drug, and Cosmetic Act; Availability 2011
    • Toggle 1 FDA Draft Guidance for Industry on Clinical Pharmacogenomics: Premarketing Evaluation in Early Phase Clinical Studies; Availability 2011
    • Toggle 1 FDA Periodic Review of Existing Regulations; Retrospective Review Under Executive Order 13563 2011
    • Toggle 1 FDA Ultra High Throughput Sequencing for Clinical Diagnostic Applications – Approaches to Assess Analytical Validity; Public Meeting; Request for Comments 2011
    • Toggle 1 FDA Draft Guidance for Industry on Medication Guide Distribution Requirements and Inclusion of Medication Guides in Risk Evaluation and Mitigation Strategies (REMS); Availability 2011
    • Toggle 1 FDA Draft Guidance for Industry and FDA Staff: Commercially Distributed In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only: Frequently Asked Questions; Availability 2011
  • Mentions in Document Text
    • Mentions
    • Agency
    • Docket
    • Date
    • Toggle 2 APHIS Monsanto Co.; Availability of Petition, Plant Pest Risk Assessment, and Environmental Assessment for Determination of Nonregulated Status for Corn Genetically Engineered for Drought Tolerance 2011
    • Toggle 1 SEC Self-Regulatory Organizations; Proposed Rule Changes: NASDAQ OMX BX, Inc. 2011
    • Toggle 1 FDA Draft Guidance for Industry and FDA Staff on Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets; Availability 2011
    • Toggle 1 EPA Improving Regulations: Economic Conditions / Market 2011
    • Toggle 1 ITA Request for Public Comments Concerning Regulatory Cooperation between the United States and the European Union that Would Help Eliminate or Reduce Unnecessary Divergences in Regulation and in Standards Used in Regulation that Impede U.S. Exports 2011
    • Toggle 1 EPA Improving Regulations: Water 2011
    • Toggle 1 FDA Draft Guidance for Industry and FDA Staff: Commercially Distributed In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only: Frequently Asked Questions; Availability 2011
    • Toggle 1 SEC Self-Regulatory Organizations; Proposed Rule Changes: NYSE Amex LLC 2011
    • Toggle 1 FDA Ultra High Throughput Sequencing for Clinical Diagnostic Applications – Approaches to Assess Analytical Validity; Public Meeting; Request for Comments 2011
    • Toggle 1 FDA Draft Guidance for Industry on Clinical Pharmacogenomics: Premarketing Evaluation in Early Phase Clinical Studies; Availability 2011

Advisory Committees

3 people on 3 committees
Information

Data is based on disclosures required by the Federal Advisory Committee Act (FACA). Matches are based on the occurrence of the company name in the committee member affiliation. Variations in company names may cause some matches to be missed.

The table shows only the top 10 agencies. To search and download raw records from the complete dataset see the FACA data section.

covers through 2011

Table shows employees of "Biotechnology Industry Organization" that sat on federal advisory committees.

  • Agency
  • Representation
  • Toggle Department of Commerce 1 person on 1 committee
  • Toggle Department of Defense 1 person on 1 committee
  • Toggle Department of Health and Human Services 1 person on 1 committee
View all advisory committee data for Biotechnology Industry Organization